Drug intelligence / Profile preview

CN-202

Development stage: Phase 2
Lead developer: Curon Biopharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CN-202 is a bispecific antibody drug candidate designed to inhibit both Programmed death-ligand 1 (PD-L1) and Transforming growth factor beta (TGF-β). It is being developed for the treatment of locally advanced or metastatic solid tumors and hematologic malignancies. The drug acts as an immune checkpoint inhibitor by targeting PD-L1, which helps cancer cells evade immune detection, and as a TGF-β inhibitor, potentially reducing tumor-induced immunosuppression. Clinical trials have evaluated its safety, tolerability, pharmacokinetics, and anti-tumor activity in adult patients with these cancers[2][3][5].

Targets

CD274 (Programmed cell death protein 1 ligand 1)TGFB (GARP–latent transforming growth factor beta 1 complex)

Beyond the preview

Go deeper on CN-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CN-202.

Explore the full profile